Pathology News
editor

About Editor

This author has not yet filled in any details.
So far Editor has created 933 blog entries.

August 2025

Study Confirms Reliability of Digital TIL Scoring in Post-Treatment Breast Cancer Assessment

2025-08-18T08:58:56+00:00

by Christos Evangelou, MSc, PhD – Medical Writer and Editor In a recent study, researchers at the Institut Jules Bordet in Belgium validated the reliability of digital scoring of tumor-infiltrating lymphocytes (TILs) in breast cancer tissue after chemotherapy treatment. The study showed that trained pathologists can consistently evaluate immune cell presence in residual tumor tissue, [...]

Study Confirms Reliability of Digital TIL Scoring in Post-Treatment Breast Cancer Assessment2025-08-18T08:58:56+00:00

Modella AI and Techcyte Announce a Research Collaboration with Modella AI’s State-of-the-Art Agentic and Generative AI-Powered Diagnostic Pathology Platform

2025-09-17T09:36:07+00:00

Techcyte, a leading provider of AI-powered digital diagnostics for anatomic and clinical pathology, today announced that its platform, Techcyte Fusion™ (research use only (RUO) in the US, CE-IVDD-marked in Europe), now includes Modella AI, a biomedical artificial intelligence company at the forefront of computational pathology, as a partner in the Techcyte Fusion Partner Program. This collaboration brings [...]

Modella AI and Techcyte Announce a Research Collaboration with Modella AI’s State-of-the-Art Agentic and Generative AI-Powered Diagnostic Pathology Platform2025-09-17T09:36:07+00:00

From Potential to Pipeline: How Pathology AI Is Rewiring Drug Discovery and Development

2025-08-27T12:28:12+00:00

Everyone’s talking about AI in therapeutic R&D, but it’s not always easy to cut through the hype to understand where it’s making a real impact today. One of the clearest signals of progress? Pathology. In a recent Drug Discovery World webinar, our Chief Strategy Officer Nathan Buchbinder sat down with industry leaders Vipul Baxi (Amgen), Dr. Deirdre De Steno (Owkin), and Dr. Ken Bloom (Nucleai) to [...]

From Potential to Pipeline: How Pathology AI Is Rewiring Drug Discovery and Development2025-08-27T12:28:12+00:00

Techcyte and Modella AI Announce a Research Collaboration with Modella AI’s State-of-the-Art Agentic and Generative AI-Powered Diagnostic Pathology Platform

2025-09-17T09:38:37+00:00

Techcyte, a leading provider of AI-powered digital diagnostics for anatomic and clinical pathology, today announced that its platform, Techcyte Fusion™ (research use only (RUO) in the US, CE-IVDD-marked in Europe), now includes Modella AI, a biomedical artificial intelligence company at the forefront of computational pathology, as a partner in the Techcyte Fusion Partner Program. This collaboration brings [...]

Techcyte and Modella AI Announce a Research Collaboration with Modella AI’s State-of-the-Art Agentic and Generative AI-Powered Diagnostic Pathology Platform2025-09-17T09:38:37+00:00

Deep Learning Assessment of Metastatic Relapse Risk From Digitized Breast Cancer Histological Slides

2025-08-27T12:28:21+00:00

Valentin Gaury (Senior Data Scientist) and colleagues at Owkin, in collaboration with Dr. Ingrid Garberis and researchers from Gustave Roussy, Paris-Saclay University (Villejuif, France), have recently published a paper on the deep learning assessment of metastatic relapse risk using digitized breast cancer histological slides. Following this recent publication, Pathology News will host a webinar where Valentin Gaury will [...]

Deep Learning Assessment of Metastatic Relapse Risk From Digitized Breast Cancer Histological Slides2025-08-27T12:28:21+00:00

EVIDENT Announces Acquisition of Pramana, Inc.

2025-08-18T13:27:12+00:00

Evident announces a definitive agreement to acquire Pramana, Inc., a leading manufacturer of digital pathology solutions. Pramana’s cutting-edge autonomous whole slide imaging technologies, combined with Evident’s longstanding leadership in clinical microscopy and superior optics, will revolutionize the market for digital pathology solutions and usher in a new era—digital pathology 2.0. Founded in 2021 by nference (a [...]

EVIDENT Announces Acquisition of Pramana, Inc.2025-08-18T13:27:12+00:00

What Happens When a Pathologist Talks to a Tablet?

2025-08-27T12:28:29+00:00

A structured report is created – in seconds. No joke. No buzzword. Reality in Bremen, Germany. At Klinikum Bremen-Mitte and the MVZ Fachärztezentrum Hanse, elea, our AI-powered software for pathology, is up and running. It doesn’t just listen. It understands. Samy Hakroush, Chief Physician of Pathology, dictates – and elea instantly understands what it’s about: [...]

What Happens When a Pathologist Talks to a Tablet?2025-08-27T12:28:29+00:00

OriGene and HistoWiz Announce New Integration to Streamline Antibody Access Through PathologyMap™

2025-08-22T09:22:27+00:00

HistoWiz is excited to announce a new collaboration with OriGene, a leading supplier of research antibodies and molecular biology tools. Through this partnership, a curated list of OriGene’s antibodies is now integrated into HistoWiz’s PathologyMap™ platform, giving researchers streamlined access to validated reagents directly within their digital pathology workflow.PathologyMap™, HistoWiz’s digital pathology image management platform, enables scientists [...]

OriGene and HistoWiz Announce New Integration to Streamline Antibody Access Through PathologyMap™2025-08-22T09:22:27+00:00

EVIDENT to Acquire Pramana, Inc.

2026-09-29T11:43:15+00:00

Evident announces a definitive agreement to acquire Pramana, Inc., a leading manufacturer of digital pathology solutions. Pramana’s cutting-edge autonomous whole slide imaging technologies, combined with Evident’s longstanding leadership in clinical microscopy and superior optics, will revolutionize the market for digital pathology solutions and usher in a new era—digital pathology 2.0. Founded in 2021 by nference (a [...]

EVIDENT to Acquire Pramana, Inc.2026-09-29T11:43:15+00:00

Leica Biosystems Unveils its Compact Capacity, Feature-Rich Digital Pathology Scanner at Asia Pacific Summit

2025-08-18T15:10:35+00:00

Reinforcing its leadership in digital pathology for cancer diagnostics and research, Leica Biosystems proudly unveiled its Aperio GT 180 scanner at the Asia Pacific Imaging Summit 2025 — 9th Digital Pathology & AI Congress. Building on more than 25 years of innovation, the Aperio GT 180 scanner represents the next step in Leica Biosystems slide scanning portfolio. While offering a more [...]

Leica Biosystems Unveils its Compact Capacity, Feature-Rich Digital Pathology Scanner at Asia Pacific Summit2025-08-18T15:10:35+00:00
Legal

Bioincyte Ltd is registered in the United Kingdom
under company number 13037659

Get in touch

© Copyright 2025, Bioincyte Ltd

Fields marked with an asterisk (*) are required.
By submitting you agree to our T&C and Privacy Policy

Go to Top